AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 21 min read$IRMD

Susi Roger E. sold $227K of IRMD (indirect holdings)

Susi Roger E. (CEO, President, Chairman) sold 2,500 indirectly-held shares of IRADIMED CORP (IRMD) at an average of $90.60 ($88.68–$91.91, $0.23M total) across 4 trades on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Susi Roger E.
Published Jun 2, 2026, 6:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IRMD
Bearish
medium confidence
Mentioned
$IRMD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRMDBearishLow
01

Why it matters

The disclosed sale is modest relative to total holdings and likely to have limited price impact.

02

Market read

Primary source filing; small insider sell with limited trading relevance.

03

What to watch

Sale executed via pre‑arranged 10b5‑1 plan, reducing informational value.

Relevance 3/10Novelty 3/10Timing: today

Background

Form 4 filing discloses insider transactions required by SEC; provides transparency on executive holdings.

Company-level read

Ticker impact

$IRMDBearishMedium confidence
Context

SEC Form 4 shows CEO sold 2,500 shares for $226.5K via 10b5‑1 plan.

Expected impact

potential slight downward pressure as market prices in insider sell

Evidence & confidence

Sale size is modest relative to holdings; typical market reaction to insider sales is modest price dip.

Market effects

Sector

Minimal impact on healthcare sector; isolated insider transaction.

Regional

No broader regional effect.

Global

Not globally relevant.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily indicate company weakness.

Key entities

  • Company
    Iradimed Corp

    Medical device manufacturer listed on Nasdaq under IRMD.

  • Person
    Susi Roger E.

    CEO, President, Chairman of Iradimed Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IRMD insider trading history →

Related articles

AUG 8
$IRMDMedAI 9/10

IRadimed (IRMD) Q2 2026 Earnings Call Transcript

IRadimed (IRMD) reported Q2 2026 revenue of $20.5 million, up 0.5% from $20.4 million a year earlier. GAAP diluted EPS was $0.41 versus $0.45, and non-GAAP EPS was $0.46. Gross margin fell to 74% from 78% due to higher manufacturing costs during the 3870 pump ramp. Q3 revenue guidance is $23.0 to $24.5 million; full-year 2026 revenue guidance is $91 to $96 million.

fool.com7 min
MAY 29
$IRMDMedAI 9/10

Iradimed Corp (IRMD): 3 Things That Stood Out From Q1 Report

Iradimed Corp (IRMD) reported Q1 2026 results on May 1. The company said revenue rose 13% year over year to $22 million and net income increased 24% to $5.8 million, or $0.45 per share. Iradimed also launched its next-generation 3870 MRI-compatible IV infusion pump in Q1, with shipments expected to begin in Q2. For Q2, it forecast revenue of $20–$21 million and GAAP EPS of $0.40–$0.44; full-year 2026 revenue of $91–$96 million and GAAP EPS of $1.90–$2.05.

finance.yahoo.com4 min
OCT 22
$DOLELow

Pale Fire Capital SE (Senkypl Dusan, Barta Jan) purchased $8.6M of DOLE (indirect holdings)

Pale Fire Capital SE purchased 648,356 indirectly-held shares of Dole plc (DOLE) at an average of $13.19 ($13.12–$13.39, $8.55M total) across 3 trades over 2026-10-20 to 2026-10-22. Filed jointly with Pale Fire Capital SICAV a.s. (10% owner), Pale Fire Capital investicni spolecnost a.s. (10% owner), Senkypl Dusan (10% owner) and Barta Jan (10% owner).

SEC EDGAR1 min